Similar articles

• Fondaparinux versus enoxaparin in acute coronary syndromes.

  Majure DT, Aberegg SK. Majure DT, et al. N Engl J Med. 2006 Jun 29;354(26):2829; author reply 2830. doi: 10.1056/NEJMc061206. N Engl J Med. 2006. PMID: 16807423 No abstract available.
• The role of low-molecular-weight heparins in the management of unstable angina and non-ST-segment elevation myocardial infarction.

  Cohen M. Cohen M. J Thromb Thrombolysis. 2001 Apr;11(2):171-4. doi: 10.1023/a:1011284902244. J Thromb Thrombolysis. 2001. PMID: 11406733 Review. No abstract available.
• 2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies.

  Coons JC, Battistone S. Coons JC, et al. Ann Pharmacother. 2008 Jul;42(7):989-1001. doi: 10.1345/aph.1L063. Epub 2008 Jun 24. Ann Pharmacother. 2008. PMID: 18577763
• Comparison of fondaparinux and enoxaparin in acute coronary syndromes.

  Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators; Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, et al. N Engl J Med. 2006 Apr 6;354(14):1464-76. doi: 10.1056/NEJMoa055443. Epub 2006 Mar 14. N Engl J Med. 2006. PMID: 16537663 Clinical Trial.
• The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.

  Haas S. Haas S. Semin Vasc Med. 2003 May;3(2):139-46. doi: 10.1055/s-2003-40672. Semin Vasc Med. 2003. PMID: 15199477 Review.